# US 2013/0273153 A1 · Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273153 A1
- Document ID: US20130273153A1
- Status: Published application
- Kind: A1
- Application number: 13/995,810
- Filed: 2011-06-22
- Published: 2013-10-17
- Earliest claimed: 2009-12-22
- Assignees: Mallinckrodt Inc.
- Inventors: Jae Han Park; Tiffani Eisenhauer; Anish Dhanarajan; Vishal K. Gupta; Stephen Overholt
- Web page: https://patentgrep.com/patent/US20130273153A1

## CPC

- A61K 9/2095: {Tabletting processes}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.

## Claims

### Claim 1

A method for the preparation of a solid dosage form pharmaceutical composition comprising a morphinan and acetaminophen, the method comprising:
(a) granulating a first mixture comprising the morphinan and at least one excipient to form a plurality of morphinan-protected granules, wherein the morphinan in the morphinan protected-granules is substantially resistant to oxidative degradation;
(b) granulating a second mixture in the presence of a granulation fluid, the second mixture comprising the plurality of morphinan-protected granules, acetaminophen, and at least one excipient to form a plurality of tablet granules; and
(c) blending the plurality of tablet granules with a release-controlling polymer comprising a polyethylene oxide polymer and optionally at least one excipient to form the solid dosage form pharmaceutical composition comprising a sustained release layer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the morphinan is chosen from adulmine, allocryptopine, aporphine, benzylmorphine, berberine, bicuculine, bicucine, bulbocapnine, buprenorphine, butorphanol, canadine, capaurine, chelerythrine, chelidonine, codamine, codeine, coptisine, coreximine, corlumine, corybulbine, corycavamine, corycavine, corydaline, corydine, corytuberine, cularine, cotamine, cryptopine, cycloartenol, cycloartenone, cyclolaudenol, dehydroreticuline, desomorphine, dextropropoxyphene, dextrorphanol, diacetylmorphine, dicentrine, dihydrosanguinarine, dipropanoylmorphine, epiporphyroxine, ethylmorphine, eupaverine, fagarine, fentanyl, glaucine, homochelidonoine, hydrocodone, hydrocotamine, hydromorphone, hydroxythebaine, isoboldine, isocorybulbine, isocorydine, isocorypalmine, isoquinoline, laudanidine, laudanine, laudanosine, levorphanol, magnoflorine, meconic acid, methadone, morphine, nalbuphine, nalmefene, naloxone, naltrexamine, α-naltrexol, β-naltrexol, naltrexone, naphthaphenanthridine, narceine, narceinone, narcotoline, narcotine, neopine, nicomorphine, norlaudanosoline, norsanguinarine, noscapine, opium, oripavine, oxycodone, oxymorphone, oxysanguinarine, palaudine, papaverine, papaveraldine, papaverrubine, perparin, pethidine, phenanthrene, phtalide-isoquinoline, porphyroxine, protopine, pseudocodeine, pseudomorphine, reticuline, salutaridine, sinoacutine, sanguinarine, scoulerine, somniferine, stepholidine, tapentadol, tetrahydroprotoberberine, thebaine, tramadol, and xanthaline.

### Claim 3 (depends on 1)

The method of claim 1, wherein the granulation in step (a) and (b) is done using a device chosen from a low-shear wet granulator, a high-shear wet granulator, a fluid-bed granulator, a roller compactor, a vertical granulator, an oscillating granulator, a gelatinizer, a pelletizer, a spheronizer, and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the excipient in step (a) or (b) is chosen from a binder, a filler, an antioxidant, a pH-adjusting agent, a chelating agent, an antimicrobial agent and combinations of any of the foregoing excipients.

### Claim 5 (depends on 1)

The method of claim 1, wherein the solid dosage form pharmaceutical composition is chosen from granules, uncoated tablets, coated tablets, mini-tablets, bilayer tablets, orally disintegrating tablets, hard capsules, and multilayer capsules.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method further comprises (d) granulating a third mixture comprising the plurality of morphinan-protected granules, the acetaminophen, and at least one excipient to form a plurality of immediate release granules.

### Claim 7 (depends on 6)

The method of claim 6 wherein the method further comprises:
(e) blending the immediate release granules with at least one excipient to form the immediate release layer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the morphinan is hydrocodone.

### Claim 9 (depends on 1)

The method of claim 1, wherein the morphinan is oxycodone.

### Claim 10

A granule substantially resistant to oxidative degradation of a morphinan selected from the group consisting of oxycodone and hydrocodone the granule comprising an interior region substantially comprising the morphinan and an exterior region substantially comprising at least one excipient chosen from a binder, a filler, an antioxidant, a chelating agent, and combinations thereof, wherein the exterior region surrounds the interior region and wherein the granule contains less than about 0.5% w/w of the total mass of a degradant after being stored for 6 months at 40° C. and 75% relative humidity.

### Claim 11 (depends on 10)

The granule of claim 10, wherein less than about 20% of the total weight of the morphinan in the granule is exposed on the surface of the granule.

### Claim 12 (depends on 10)

The granule of claim 10, further comprising at least one additional active pharmaceutical ingredient.

### Claim 13 (depends on 12)

The granule of claim 12, wherein the at least one additional active pharmaceutical ingredient is acetaminophen.

### Claim 14

A solid dosage pharmaceutical composition comprising a plurality of morphinan-protected granules and acetaminophen, the composition prepared by a process comprising:
(a) granulating a first mixture comprising the morphinan and at least one excipient to form the plurality of morphinan-protected granules, wherein the morphinan in the morphinan-protected granules is substantially resistant to oxidative degradation;
(b) granulating a second mixture in the presence of a granulation fluid, the second mixture comprising the plurality of morphinan-protected granules, the acetaminophen, and at least one additional excipient to form a plurality of tablet granules; and
(c) blending the plurality of tablet granules with a release-controlling polymer and optionally at least one carrier to form the solid dosage pharmaceutical composition comprising a sustained release layer.

### Claim 15 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, further comprising step (d) which includes granulating a third mixture in the presence of a granulation fluid, the third mixture comprising morphinan-protected granules, acetaminophen, and at least one additional excipient to form a plurality of immediate release granules, and step (e) blending the immediate release granules with at least one excipient to form an immediate release layer.

### Claim 16 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, wherein less than about 30% of the total weight of the morphinan in the tablet-protected granules is exposed on the surface of the granules.

### Claim 17 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, wherein the at least one pharmaceutically acceptable carrier is incompatible with the morphinan.

### Claim 18 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, wherein the morphinan is oxycodone and the degradant is selected from 10-hydroxy oxycodone, di-hydroxy oxycodone, and oxycodone n-oxide.

### Claim 19 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, wherein the morphinan is hydrocodone and the degradant is selected from hydrocodone-n-oxide and hydrocodone aldol dimer.

### Claim 20 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, wherein the release-controlling polymer is a hydrophilic polymer.

### Claim 21 (depends on 14)

The solid dosage pharmaceutical composition of claim 14, wherein the hydrophilic polymer is a polyethylene oxide.
